+44 79 19 49 39 39 wilsonblaney@gmail.com

Pennywise And Billion-Foolish: Troubling Data For Pfizer’s Ian Read
Since its creation in 1989, Bristol-Myers Squibb has brought to market about the same number of new drugs as Pfizer—26 vs. Pfizer’s 25 (Figure 1). Their cumulative R&D spending, however, diverges widely. BMS did for $ 56 billion, while Pfizer has spent …
Read more on Forbes


Pfizer Inc.’s Best Drug in 2015
If you’re a shareholder in pharmaceutical giant Pfizer (NYSE:PFE), it might feel as if it’s been a rather ho-hum year. The stock has traded in a fairly tight range (not that Pfizer is all that volatile to begin with), but it’s managed to tick slightly …
Read more on Motley Fool